COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine
After a single 25mg dose of COMP360 psilocybin therapy, approximately 30% of patients with treatment-resistant…
Your Next Customer Isn’t Googling You. They’re Asking AI
Rhino Propels Federated AI into the Enterprise Tech Stack